$Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach$
Código QR

Código QR

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach

Purpose: Triple-negative breast cancer (TNBC) is well known for its aggressive course and poor prognosis. In this study, we sought to investigate clinical, demographic, and pathologic characteristics and treatment outcomes of patients with refractory, metastatic TNBC selected by a clinical data ware...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hana Kim, Hyo Jung Kim, Hongsik Kim, Hye Ryeon Kim, Hyunji Jo, Joohyun Hong, Ryul Kim, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Se Kyung Lee, Haeyoung Kim, Soo-Yong Shin, Yeon Hee Park
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	metastatic breast cancer triple-negative breast cancer CDW Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d828e4c6b0b945f582face840a235607
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Mohamad Adham Salkeni, et al.
Publicado: (2017)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Giacomo Barchiesi, et al.
Publicado: (2021)

Tumor suppressive function of Matrin 3 in the basal-like breast cancer
por: Yang,Jaehyuk, et al.
Publicado: (2020)

Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer
por: Cenzhu Wang, et al.
Publicado: (2021)

Metastatic Breast Cancer to the Urinary Bladder in the Caribbean
por: Saara Mohammed, et al.
Publicado: (2021)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Alyssa Vito, et al.
Publicado: (2021)

Effect of statins on breast cancer recurrence and mortality: a review
por: Van Wyhe RD, et al.
Publicado: (2017)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
por: Peng Su, et al.
Publicado: (2021)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Alberto Aranza-Martínez, et al.
Publicado: (2021)

Dietary Factors and Breast Cancer Prognosis among Breast Cancer Survivors: A Systematic Review and Meta-Analysis of Cohort Studies
por: Sin-Hye Park, et al.
Publicado: (2021)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
por: Selase Ativui, et al.
Publicado: (2021)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021)

Breast cancer

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

<i>SMARCA4</i> Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer
por: Jihyun Kim, et al.
Publicado: (2021)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis
por: Dara Brena, et al.
Publicado: (2022)

Current medical literature.

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer
por: Hongyuan Zhao, et al.
Publicado: (2021)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
por: Al-saraireh YM, et al.
Publicado: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
por: Abdulwahab Abuderman, et al.
Publicado: (2020)

Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)
por: Jae Sik Kim, et al.
Publicado: (2021)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li Y, et al.
Publicado: (2020)

Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells
por: Veronica Vella, et al.
Publicado: (2021)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Miyuki Kitahara, et al.
Publicado: (2021)

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
por: Ilie SM, et al.
Publicado: (2018)

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
por: Jiaojiao Suo, et al.
Publicado: (2021)

Advances in breast cancer
Publicado: (2004)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Hye Ryeon Kim, et al.
Publicado: (2021)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
por: Zuo R, et al.
Publicado: (2021)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: Luis de la Cruz-Merino, et al.
Publicado: (2021)

Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
por: Hae Hyun Jung, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system
por: Rashid N, et al.
Publicado: (2016)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni A, et al.
Publicado: (2016)